Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of TMC125 with darunavir/ritonavir plus optimized background regimen in DUET trial participants with virologic failure
2006-001287-23Phase 3Completed
- Sponsor
- Tibotec
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etravirine, darunavir and ritonavir in Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Long-term safety and tolerability. Started Apr 2006; status: completed.
02
Drugs
etravirinedarunavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-001287-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001287-23.